FYU 981

Drug Profile

FYU 981

Alternative Names: FYU981

Latest Information Update: 21 Feb 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Fuji Yakuhin
  • Class Uricosurics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hyperuricaemia

Most Recent Events

  • 06 Apr 2017 Fuji Yakuhin plans a phase III trial for Hyperuricaemia in Japan (NCT03100318)
  • 01 Dec 2016 Phase-III clinical trials in Hyperuricaemia in Japan (PO)
  • 01 Nov 2016 Fuji Yakuhin completes a phase II trial (In volunteers) in Japan (NCT02515864)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top